Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection.

X
Trial Profile

Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATX-GD 59 (Primary)
  • Indications Graves' disease
  • Focus Adverse reactions; First in man
  • Sponsors Apitope Technology
  • Most Recent Events

    • 13 Sep 2019 According to an Apitope Technology media release, the company announced that this first in human clinical trial for the treatment of Graves' disease funded by the European Union (DAVIAD) has been published as a "Success Story" on the European Union website. The article entitled 'New treatment on the horizon for Graves' disease can be viewed in the following link: https://ec.europa.eu/research/infocentre/article_en.cfm?artid=50625
    • 16 Apr 2018 According to an Apitope Technology media release, company has announced positive results from this trial.This study met the primary endpoint to assess the safety and tolerability of ATX-GD-59 in 12 patients with Graves' disease.
    • 19 Feb 2018 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top